Congenital Adrenal Hyperplasia
Conditions
Keywords
Adrenocortical function, Adrenal hyperplasia, Congenital, 21-hydroxylase deficiency, Adrenogenital Syndrome, Adolescents, Female, Hyperplasia, Adrenal Gland Diseases, Congenital Abnormalities, Adrenocortical Hyperfunction, Disorders of Sex Development, Endocrine System Diseases, Genetic Diseases, Inborn, Gonadal Disorders, Metabolic Diseases, Metabolism, Inborn Errors, Pathologic Processes, Steroid Metabolism, Inborn Errors, Urogenital Abnormalities, Corticotropin Releasing Factor
Brief summary
This is a Phase 1, multicenter, open-label, single-dose study to evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-77860 in subjects with congenital adrenal hyperplasia (CAH). The study will be conducted in approximately 15 adolescent females (12-18 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency CAH. The study will include three independent dose cohorts of NBI-77860 (approximately 5 subjects per dose cohort). Ascending doses will be evaluated as part of a sequential-cohort design.
Interventions
DRUGNBI-77860
Sponsors
Neurocrine Biosciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Have documentation of written informed consent, or written and witnessed assent from the subject and written informed consent from the subject's parent or legal guardian. 2. Be in good general health. 3. Have a medically confirmed diagnosis of classic 21-hydroxylase deficiency CAH. 4. Be on a stable regimen of steroidal treatment for CAH for a minimum of 30 days before baseline (Night 1) that is expected to remain stable throughout the study. 5. Subjects of childbearing potential must be instructed on the proper use of barrier methods of contraception and agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently from screening until the final study visit or 30 days after the last dose of study drug, whichever is longer. 6. Subjects of childbearing potential must have a negative pregnancy test at screening and negative urine pregnancy test at baseline (Night 1). 7. Have a negative urine drug (for illegal drugs) and alcohol breath test at screening and baseline (Night 1). 8. Be willing and able to adhere to the study regimen and study procedures described in the protocol and informed consent/assent form, including all requirements at the study center and return for the follow-up visit. 9. Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA).
Exclusion criteria
1. Have a clinically significant unstable medical condition or chronic disease, or malignancy. 2. Had a medically significant illness within 30 days of screening. 3. Have a known or suspected differential diagnosis of any of the other known forms of classic CAH. 4. Have a history that includes bilateral adrenalectomy, hypopituitarism, or other condition requiring daily therapy with orally administered glucocorticoids. 5. Pregnant or lactating females. 6. Have a history of epilepsy or serious head injury. 7. Test positive at screening for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV), or have a history of a positive result. 8. Have a recent history (≤1 year) of alcohol or drug abuse, or current evidence of substance dependence or abuse criteria. 9. Used any other investigational drug within 30 days before initial screening, or plans to use an investigational drug (other than the study drug) during the study. 10. Have a blood loss ≥250 mL or donated blood within 56 days or donated plasma within 7 days before baseline. 11. Self-report consumption of more than 6 caffeine-containing beverages a day within the last month before baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events following one oral dose of NBI-77860 | Up to 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Area Under Concentration Curve (AUC) of NBI-77860 and its metabolites following one oral dose of NBI-77860 | Night 1 and Days 2, 7, 14, 21 and 35 (or early termination) |
| Concentrations of 17-hydroxyprogesterone (17-OHP) following one oral dose of NBI-77860 | Screening, Night 1, Day 2 (10, 12 and 24 hours postdose) and 35 (or early termination) |
| Concentrations of adrenocorticotropin hormone (ACTH) following one oral dose of NBI-77860 | Screening, Night 1, Day 2 (10, 12 and 24 hours postdose) and 35 (or early termination) |
Countries
United States
Outcome results
None listed